

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number
WO 2005/035569 A3

(51) International Patent Classification:
C07K 14/47 (2006.01)

(21) International Application Number:
PCT/US2004/033408

(22) International Filing Date: 12 October 2004 (12.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/510,612 10 October 2003 (10.10.2003) US

(71) Applicant (for all designated States except US): FIVE
PRIME THERAPEUTICS, INC. [US/US]; 951 Gateway
Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WONG, Justin, G.,
P. [US/US]; 389 Somerset Road, Apartment 3, Oakland,
CA 94611 (US). HESTIR, Kevin [US/US]; 226 Arlington
Avenue, Kensington, CA 94707 (US). COLLINS, Amy,
L., Tsui [US/US]; 5955 Girvin Drive, Oakland, CA 94611
(US).

(74) Agent: GARRETT, Arthur, S.; Finnegan, Henderson,
Farabow, Garrett & Dunner, L.L.P., 901 New York Avenue,
NW, Washington, D.C. 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
2 March 2006

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: KIAA0779, SPLICE VARIANTS THEREOF, AND METHODS OF THEIR USE

(57) Abstract: The invention provides novel polynucleotides, related polypeptides related nucleic acid and polypeptide composi-
tions, and related modulators, such as antibodies and small molecule modulators. The invention also provides methods to make and
use these polynucleotides, polypeptides, related compositions, and modulators. These methods include diagnostic, prophylactic, and
therapeutic applications. The compositions and methods of the invention are useful in treating proliferative disorders, e.g., cancers,
such as kidney and pancreatic cancer; and inflammatory, immune, and viral disorders.

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/033408

A. CLASSIFICATION OF SUBJECT MATTER
C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, Sequence Search, WPI Data, BIOSIS, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE Geneseq 'Online! 6 November 2001 (2001-11-06), "Human polynucleotide SEQ ID NO 800." XP002331290 retrieved from EBI accession no. GSN:AAI80740 Database accession no. AAI80740 abstract</p> <p style="text-align: center;">----- -/--</p>	<p>1-10, 14, 16, 17, 27, 29, 31-33</p>

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

20 June 2005

Date of mailing of the international search report

20. 12. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Young, C

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US2004/033408

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! 15 November 2002 (2002-11-15), "Homo sapiens transmembrane and coiled-coil domains 1, transcript variant 1, mRNA (cDNA clone MGC:48954 IMAGE:5527623), complete cds." XP002331291 retrieved from EBI accession no. EM_PRO:BC039859 Database accession no. BC039859 abstract</p>	1-10,14, 16,17, 27,29, 31-33
X	<p>DATABASE UniProt 'Online! 16 October 2001 (2001-10-16), "Transmembrane and coiled-coil domains protein 1." XP002331292 retrieved from EBI accession no. UNIPROT:TMCC1_HUMAN Database accession no. TMCC1_HUMAN abstract</p>	1-10,14, 16,17, 27,29, 31-33
X	<p>PNAS, 24 December 2002 (2002-12-24), XP002245220</p> <p>the whole document</p>	1-10,14, 16,17, 27,29, 31-33
X	<p>DATABASE EMBL 'Online! 9 September 1999 (1999-09-09), "wt80d04.x1 Soares_thymus_NHFT Homo sapiens cDNA clone IMAGE:2513767 3', mRNA sequence." XP002331293 retrieved from EBI accession no. EM_PRO:AI989368 Database accession no. AI989368 abstract</p>	1-10,14, 16,17, 27,29, 31-33

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/033408

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-10, 14, 16, 17, 27, 29, 31, 32, 33 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-10, 14,16,17, 27,29,31,32,33 (partially)

claims relating to the polynucleotide represented by SEQ ID NO.1

2. claims: 1-10, 14,16,17, 27,29,31,32,33 (partially)

claims relating to the polynucleotide represented by SEQ ID NO. 2

3. claims: 1-10, 14,16,17, 27,29,31,32,33 (partially)

claims relating to the polynucleotide represented by SEQ ID NO. 4

4. claims: 1-10, 14,16,17, 27,29,31,32,33 (partially)

claims relating to the polynucleotide represented by SEQ ID NO. 5

5. claims: 1-10, 14,16,17, 27,29,31,32,33 (partially)

claims relating to the polynucleotide represented by SEQ ID NO. 31

6. claims: 1-10, 14,16,17, 27,29,31,32,33 (partially)

claims relating to the polynucleotide represented by SEQ ID NO. 32

7. claims: 1-10, 14,16,17, 27,29,31,32,33 (partially)

claims relating to the polynucleotide represented by SEQ ID NO. 35

8. claims: 1-10, 14,16,17, 27,29,31,32,33 (partially)

claims relating to the polynucleotide represented by SEQ ID NO. 36

9. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
7

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
8

11. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
10

12. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
11

13. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
12

14. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
13

15. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
14

16. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
15

17. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
16

18. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
17

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

19. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
18

20. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
19

21. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
20

22. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
21

23. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
22

24. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
23

25. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
24

26. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
25

27. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
26

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

28. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
27

29. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
28

30. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
29

31. claims: 11-13,15,18-26,28,30,33-51(partially)

claims relating to the polypeptide represented by SEQ ID NO.
30

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.